Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment

NCT01853046 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms

Interventions

DRUG: Regorafenib (Stivarga, BAY73-4506)

Sponsor

Bayer